MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
AbbVie Accounts Receivables 2011-2026 | ABBV
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.6 B | 10.9 B | 11.2 B | 11.3 B | 9.98 B | 8.82 B | 5.43 B | 5.38 B | - | 4.76 B | 4.73 B | 3.74 B | 3.85 B | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.6 B | 3.74 B | 7.72 B |
Quarterly Accounts Receivables AbbVie
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.8 B | 12.6 B | 12.5 B | 11.5 B | 11.7 B | 11.9 B | 11.4 B | 11.5 B | 11.5 B | 11.3 B | 10.7 B | - | 10.7 B | 9.98 B | 9.28 B | 9.91 B | 9.59 B | 8.82 B | 8.82 B | 8.82 B | 8.82 B | 5.43 B | 5.43 B | 5.43 B | 5.43 B | 5.38 B | 5.38 B | 5.38 B | 5.38 B | 5.09 B | 5.09 B | 5.09 B | 5.09 B | 4.76 B | 5 B | 4.76 B | 4.76 B | 4.73 B | 4.57 B | 4.73 B | 4.73 B | 3.74 B | 3.74 B | 3.74 B | 3.74 B | 3.85 B | 3.85 B | 3.85 B | 3.85 B | 4.3 B | 4.3 B | 4.3 B | 4.3 B | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.8 B | 3.74 B | 6.99 B |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
366 M | $ 20.32 | -1.86 % | $ 2.56 B |  USA |
 |
Aptorum Group Limited
APM
|
62.2 K | $ 0.82 | -2.7 % | $ 4.47 M |  China |
 |
Axsome Therapeutics
AXSM
|
224 M | $ 165.39 | -0.6 % | $ 8.23 B | USA |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M | China |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 3.65 | -4.58 % | $ 1.09 B |  Canada |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
26 K | $ 17.24 | -3.63 % | $ 828 M | USA |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M | Canada |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
25 M | $ 0.99 | -2.59 % | $ 72.7 M | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
800 K | $ 3.18 | -4.94 % | $ 1.14 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Agios Pharmaceuticals
AGIO
|
3.43 M | $ 28.47 | -2.5 % | $ 1.65 B | USA |
 |
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | USA |
 |
Albireo Pharma
ALBO
|
3.27 M | - | -0.23 % | $ 916 M | USA |
 |
Altimmune
ALT
|
544 K | $ 4.15 | -0.24 % | $ 295 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
126 M | $ 24.06 | 0.75 % | $ 2.94 B | USA |
 |
Amarin Corporation plc
AMRN
|
127 M | $ 13.95 | 0.14 % | $ 5.79 B |  Irlanda |
 |
Blueprint Medicines Corporation
BPMC
|
75.8 M | - | - | $ 8.14 B | USA |